AstraZeneca, the United Kingdom’s most valuable listed business, has announced a pause on its planned £200 million expansion at the Cambridge research hub, dealing a substantial setback to the government’s
AstraZeneca, the United Kingdom’s most valuable listed business, has announced a pause on its planned £200 million expansion at the Cambridge research hub, dealing a substantial setback to the government’s






